Sign In
Buy PIRS
$13.60
+0 (+0%)
At Close: Mar 12, 2025
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
08:00am, Wednesday, 18'th May 2022
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo
4 Stocks Under $3 Insiders Are Aggressively Buying
12:10pm, Tuesday, 17'th May 2022 Benzinga
US crude oil futures traded slightly lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence o
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
01:35pm, Monday, 16'th May 2022 Zacks Investment Research
The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
11:17am, Monday, 16'th May 2022
The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
12:45pm, Wednesday, 11'th May 2022 Zacks Investment Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals, Inc (PIRS) CEO Stephen S. Yoder on Q1 2022 Results - Earnings Call Transcript
10:43am, Wednesday, 11'th May 2022
Pieris Pharmaceuticals, Inc (NASDAQ:PIRS ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Stephen S. Yoder – Chief Executive Officer, President, Director Thomas Bures
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
09:47am, Wednesday, 11'th May 2022
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
08:00am, Wednesday, 04'th May 2022
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog
3 Risky Stocks With Huge Potential Upside
03:00pm, Friday, 15'th Apr 2022 The Motley Fool
Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.
This Pharmaceutical Stock Could Be Your Lottery Ticket
10:00am, Saturday, 09'th Apr 2022 The Motley Fool
Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.
This Pharmaceutical Stock Could Be Your Lottery Ticket
06:00am, Saturday, 09'th Apr 2022
Pieris Pharmaceuticals has several drugs in clinical trials, but it only takes one to make this stock a hit.
This Pharmaceutical Stock Could Bank Billions Soon
10:15am, Friday, 08'th Apr 2022 The Motley Fool
Pieris Pharmaceuticals has several collaborations in place with big pharma.
This Pharmaceutical Stock Could Bank Billions Soon
06:15am, Friday, 08'th Apr 2022
Pieris Pharmaceuticals has several collaborations in place with big pharma.
3 Biotechs That Will Crush the Bear
09:00pm, Friday, 11'th Mar 2022 The Motley Fool
Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.
3 Biotechs That Will Crush the Bear
09:00pm, Friday, 11'th Mar 2022 The Motley Fool
Our roundtable likes Doximity, Outset Medical, and Pieris Pharmaceuticals to outperform in 2022.
